Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Operations: 2023-2024

Historic Cash from Operations for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to -$194.4 million.

  • Inhibrx Biosciences' Cash from Operations fell 11.70% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$143.4 million, marking a year-over-year increase of 30.90%. This contributed to the annual value of -$194.4 million for FY2024, which is 0.57% down from last year.
  • According to the latest figures from FY2024, Inhibrx Biosciences' Cash from Operations is -$194.4 million, which was down 0.57% from -$193.3 million recorded in FY2023.
  • Inhibrx Biosciences' 5-year Cash from Operations high stood at -$193.3 million for FY2023, and its period low was -$194.4 million during FY2024.
  • For the 2-year period, Inhibrx Biosciences' Cash from Operations averaged around -$193.9 million, with its median value being -$193.9 million (2023).
  • Data for Inhibrx Biosciences' Cash from Operations shows a maximum YoY dropped of 0.57% (in 2024) over the last 5 years.
  • Inhibrx Biosciences' Cash from Operations (Yearly) stood at -$193.3 million in 2023, then dropped by 0.57% to -$194.4 million in 2024.